777931-67-6

Usage

Uses

Used in Pharmaceutical Industry:
3-Bromo-2-chloro-6-methoxypyridine is utilized as a building block in the pharmaceutical industry for the synthesis of various medicinal compounds. Its unique structure and functional groups make it a valuable component in the development of new drugs and therapeutic agents.
Used in Organic Synthesis:
3-BROMO-2-CHLORO-6-METHOXYPYRIDINE serves as an intermediate in organic synthesis, enabling the creation of a wide range of chemical products. Its reactivity and functional groups facilitate the formation of new chemical bonds and the synthesis of complex molecules.
Used in Agrochemicals:
3-Bromo-2-chloro-6-methoxypyridine is employed as an intermediate in the synthesis of agrochemicals, contributing to the development of effective and targeted pesticides, herbicides, and other agricultural products. Its role in this industry is crucial for enhancing crop protection and yield.
Used in Specialty Chemicals:
3-BROMO-2-CHLORO-6-METHOXYPYRIDINE also finds application in the synthesis of specialty chemicals, which are tailored for specific industries such as coatings, adhesives, and polymers. Its unique properties allow for the creation of high-performance materials with specialized characteristics.

InChI:InChI=1/C6H5BrClNO/c1-10-5-3-2-4(7)6(8)9-5/h2-3H,1H3

Upstream product

• 18368-63-3 6-chloro-2-picoline 
• 17228-64-7 6-chloro-2-methoxypyridine 
• 2402-78-0 2,6-dichloropyridine 

Downstream Products

• 1585241-75-3 tert-butyl 3-((2S,3S)-5-(tert-butoxy)-3-(2-((4-methoxybenzyl)oxy)ethyl)-1-nitro-4,5-dioxopentan-2-yl)-6-methoxypicolinate 
• 1585241-87-7 1-benzyl 2-(tert-butyl) (2R,3S,4S)-4-(2-(tert-butoxycarbonyl)-6-methoxypyridin-3-yl)-3-(2-((4-methoxybenzyl)oxy)ethyl)pyrrolidine-1,2-carboxylate 
• 1585241-76-4 1-benzyl 2-(tert-butyl) (2S,3S,4S)-4-(2-(tert-butoxycarbonyl)-6-methoxypyridin-3-yl)-3-(2-((4-methoxybenzyl)oxy)ethyl)pyrrolidine-1,2-carboxylate 
• 1585241-88-8 1-benzyl 2-(tert-butyl) (2S,3S,4S)-4-(2-(tert-butoxycarbonyl)-6-methoxypyridin-3-yl)-3-(2-hydroxyethyl)pyrrolidine-1,2-dicarboxylate 
• 1585241-77-5 2-((2R,3S,4S)-1-((benzyloxy)carbonyl)-2-(tert-butoxycarbonyl)-4-(2-(tert-butoxycarbonyl)-6-methoxypyridin-3-yl)-pyrrolidin-3-yl)acetic acid 
• 1585241-97-9 C₃₅H₄₀N₂O₁₀ 
• 1585241-99-1 C₂₉H₃₈N₂O₉ 
• 1357946-21-4 3-bromo-6-methoxy-1H-pyrazolo[3,4-b]pyridine 

Relevant academic research and scientific papers

Synthesis and bioevaluation of N-(3,4,5-trimethoxyphenyl)-1H-pyrazolo[3,4-b]pyridin-3-amines as tubulin polymerization inhibitors with anti-angiogenic effects

A new series of N-(3,4,5-trimethoxyphenyl)-1H-pyrazolo[3,4-b]pyridin-3-amine derivatives as tubulin polymerization inhibitors were synthesized, and evaluated for the anti-proliferative activities. A structure–activity relationship study revealed that the free amino moiety of 1H-pyrazolo[3,4-b]pyridin-3-amine played an essential role in the anti-proliferative activities. Especially, compound 15c displayed the strongest anti-proliferation against MCF-7 cells with IC50 value of 0.067 ± 0.003 μM, and high selectivity over the normal human embryonic lung WI-38 cells with IC50 value of 23.41 ± 1.53 μM. Further mechanistic studies revealed that 15c showed strong anti-tubulin polymerization activity, changed the morphology of tubulin, and arrested the cell cycle at the G2/M transition in MCF-7 cells. Molecular docking analysis suggested that 15c well occupied the colchicine-binding pocket of tubulin. Additionally, 15c demonstrated anti-angiogenic activities with blocking the migration, invasion and tube formation, disrupting the newly formed tube, and regulating both MMP-9 and TIMP-1 in HUVEC cells. In summary, our results highlight that compound 15c is a potential antitumor compound that are worthy of further development.

The discovery of a pan-genotypic, primer grip inhibitor of HCV NS5B polymerase

The development of a series of novel 7-azabenzofurans exhibiting pan-genotype inhibition of HCV NS5B polymerase via binding to the primer grip site is presented. Many challenges, including poor oral bioavailability, high clearance, bioactivation, high human serum shift, and metabolic stability were encountered and overcome through SAR studies. This work culminated in the selection of BMS-986139 (43) as a preclinical candidate.

Practical total syntheses of acromelic acids A and B

Practical total syntheses of acromelic acids A (1) and B (2), which were scarce natural products isolated from toxic mushroom by Shirahama and Matsumoto, were accomplished in 13 (36% total yield) and 17 steps (6.9% total yield), respectively, from 2,6-dichloropyridine (8). Beginning with regioselective transformation of symmetric 8 by either ortho-lithiation or bromination, nitroalkenes 15 and 16 were provided. Stereoselective construction of the vicinal stereocenters at the C-3, 4 positions of 1 and 2 was performed by a Ni-catalyzed asymmetric conjugate addition of α-ketoesters to the nitroalkenes. Construction of the pyrrolidine ring was accomplished in a single operation via a sequence consisting of reduction of the nitro group, intramolecular condensation with the ketone, and reduction of the resulting ketimine.

Practical total syntheses of acromelic acids A and B

Practical total syntheses of acromelic acids A (1) and B (2), which have potent neuro-excitatory activity, were accomplished in 13 (36% total yield) and 17 steps (6.9% total yield), respectively, from 2,6-dichloropyridine (8). Regioselective transformation of symmetric 8 provided nitroalkenes 15 and 16. The pyrrolidine ring was efficiently constructed by Ni-catalyzed asymmetric conjugate addition followed by intramolecular reductive amination.

INHIBITOR OF CASEIN KINASE 1DELTA AND CASEIN KINASE 1EPSILON

There is provided an inhibitor that inhibits casein kinase 1δ and casein kinase 1ε, and thus, there is also provided a pharmaceutical agent useful for the treatment and/or prevention of a disease, with the pathological condition of which the mechanism of activation of casein kinase 1δ or casein kinase 1ε is associated. Particularly, the above-described inhibitor is used to provide a pharmaceutical agent useful for the treatment of circadian rhythm disorder (including sleep disorder), central neurodegenerative disease, and cancer. An inhibitor of casein kinase 1δ and casein kinase 1ε, which comprises, as an active ingredient, an oxazolone derivative represented by the following general formula (1), a salt thereof, a solvate thereof, or a hydrate thereof: [wherein, in the formula (1), each of R1 and R2 independently represents any one of a substituted or unsubstituted 6-membered or 5-membered heterocyclic group optionally having a condensed ring, a substituted or unsubstituted aromatic hydrocarbon group optionally having a condensed ring, and a substituted or unsubstituted aromatic hydrocarbon lower alkyl group or aromatic hydrocarbon lower alkenyl group optionally having a condensed ring.]